login
  Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 




Featured Highlights
21 - 40 of 150   Items
MORE study data provide insight into predicting SIRT treatment outcomes

MORE study data provide insight into predicting SIRT treatment outcomes

Thursday, 23 Jan 2014
Investigators from the MORE (Metastatic colorectal cancer liver metastases outcomes after radioembolization) study have released new findings at the American Society of Clinical Oncology’s 2014 Gastrointestinal Cancers Symposium confirming that standard laboratory tests are a valuable tool for predicting patient outcomes prior to Selective Internal Radiation Therapy (SIRT). MORE study data provide insight into predicting SIRT treatment outcomes
Cryoablation provides pain relief for patients with metastatic tumours

Cryoablation provides pain relief for patients with metastatic tumours

Sunday, 19 Jan 2014
Cryoablation kills tumours and provides pain relief to patients whose cancer has spread to the bone and soft tissue, suggests research being presented at the 6th annual Symposium on Clinical Interventional Oncology (CIO), in collaboration with the International Symposium on Endovascular Therapy (ISET). Cryoablation provides pain relief for patients with metastatic tumours
Ten-year Spanish experience shows SIRT achieves disease control in over 80% hepatocellular carcinoma patients

Ten-year Spanish experience shows SIRT achieves disease control in over 80% hepatocellular carcinoma patients

Tuesday, 14 Jan 2014
The Clínica Universidad de Navarra (CUN), Pamplona, Spain, recently celebrated its tenth anniversary of using Yttrium-90 (Y-90) microsphere radioembolization for the treatment of liver cancer. Ten-year Spanish experience shows SIRT achieves disease control in over 80% hepatocellular carcinoma patients
Effectiveness of percutaneous cryoablation for stage IA/B renal cell carcinoma approaches that of gold standard, surgery

Effectiveness of percutaneous cryoablation for stage IA/B renal cell carcinoma approaches that of gold standard, surgery

Monday, 13 Jan 2014
A prospective single-arm, five-year study has found that CT-guided percutaneous cryoablation for renal cell carcinoma offers very high efficacy, approaching that of the gold standard, surgery. Cryoablation also has a more favourable safety profile. Effectiveness of percutaneous cryoablation for stage IA/B renal cell carcinoma approaches that of gold standard, surgery

Launch of Hepatic Oncology: a journal dedicated to the management of cancers of the liver

Friday, 10 Jan 2014
Future Medicine Ltd has announced the launch of a new journal, Hepatic Oncology. This new title focuses specifically on the specialism of hepatic cancer, including both primary and secondary malignancies. Launch of Hepatic Oncology: a journal dedicated to the management of cancers of the liver
Interventional oncologists begin running US National Cancer Institute cooperative group trial

Interventional oncologists begin running US National Cancer Institute cooperative group trial

Friday, 20 Dec 2013
An important opportunity has opened up for interventional oncologists as WCIO leaders take the helm of the E1208 trial. Michael C Soulen writes that the change in the trial leadership from medical oncology to interventional oncology represents a challenge because it rests on the question: can interventional oncologists run a successful cooperative group trial of image-guided therapy? Interventional oncologists begin running US National Cancer Institute cooperative group trial
Surefire Medical completes patient enrolment in COSY trial

Surefire Medical completes patient enrolment in COSY trial

Wednesday, 11 Dec 2013
The trial evaluates eliminating coiling by using the anti-reflux Surefire Infusion System in radioembolization procedures in liver cancer. Surefire Medical completes patient enrolment in COSY trial

FDA grants Orphan Drug Designation to Lipiodol injection for management of patients with known hepatocellular carcinoma

Tuesday, 22 Oct 2013
Guerbet has announced that it has been granted Orphan Drug Designation from the US Food and Drug Administration Office of Orphan Products Development (OOPD) for Lipiodol (ethiodised oil) injection for management of patients with known hepatocellular carcinoma. FDA grants Orphan Drug Designation to Lipiodol injection for management of patients with known hepatocellular carcinoma
NHS England makes selective internal radiation therapy (SIRT) available via new commissioning procedure

NHS England makes selective internal radiation therapy (SIRT) available via new commissioning procedure

Wednesday, 02 Oct 2013
The NHS revision of Clinical Policy Commissioning Statement on SIRT will allow patients in England with metastatic colorectal cancer and intrahepatic cholangiocarcinoma who may benefit from the therapy to get treatment in specialist NHS centres. NHS England makes selective internal radiation therapy (SIRT) available via new commissioning procedure

AngioDynamics highlighted new offerings at CIRSE 2013

Friday, 20 Sep 2013
Angiovac cannula and cardiopulmonary bypass circuit, Bioflo peripherally inserted central catheters, Nanoknife system, Nevertouch direct fibre and Acculis microwave system illustrate strength of company’s portfolio. AngioDynamics highlighted new offerings at CIRSE 2013
Benefits of thermal ablation in the lung in conjunction with other therapies “cannot be overstated”

Benefits of thermal ablation in the lung in conjunction with other therapies “cannot be overstated”

Friday, 23 Aug 2013
Thomas Vogl, Institute of Diagnostic and Interventional Radiology, Goethe University, Frankfurt, spoke at ECIO (19–22 June, Budapest Hungary) about novel lung ablative techniques and the evidence for combination ablative therapies. Benefits of thermal ablation in the lung in conjunction with other therapies “cannot be overstated”
ThermoDox HEAT study results to be presented at ILCA 2013

ThermoDox HEAT study results to be presented at ILCA 2013

Thursday, 22 Aug 2013
The presentation will include the most recent overall survival data. Recent HEAT study post-hoc analysis, strongly suggest positive progression-free survival and overall survival in ThermoDox treated patients when heating cycles from the radiofrequency ablation procedure were optimised. ThermoDox HEAT study results to be presented at ILCA 2013
Tumour measurements predict survival in advanced non-small cell lung cancer

Tumour measurements predict survival in advanced non-small cell lung cancer

Wednesday, 21 Aug 2013
For the two-thirds of lung cancer patients with locally advanced or metastatic disease, tumour size is not used currently to predict overall survival times. A new study, however, led by UT Southwestern Medical Center researchers has shown that even in advanced stages, total tumour size can have a major impact on survival. Tumour measurements predict survival in advanced non-small cell lung cancer
Older liver cancer patients respond to radioembolization as well as younger patients, study says

Older liver cancer patients respond to radioembolization as well as younger patients, study says

Tuesday, 13 Aug 2013
Results of an analysis by members of the multicentre European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY), published online in late May in the Journal of Hepatology, may have important implications for older patients with inoperable primary liver cancer. Older liver cancer patients respond to radioembolization as well as younger patients, study says

Noted interventional radiologists join Surefire Medical’s scientific advisory board

Tuesday, 13 Aug 2013
Surefire Medical has announced that Gordon McLennan, Cleveland Clinic and Fred Moeslein, University of Maryland Medical Center, have joined the company’s scientific advisory board. Noted interventional radiologists join Surefire Medical’s scientific advisory board
NICE recommends selective internal radiation therapy for treatment of primary and secondary liver cancer

NICE recommends selective internal radiation therapy for treatment of primary and secondary liver cancer

Wednesday, 31 Jul 2013
BTG announced on 30 July that the National Institute for Health and Clinical Excellence (NICE) has issued guidance recommending the use of selective internal radiation therapy (SIRT), which includes TheraSphere, for patients with liver cancer across the NHS. NICE recommends selective internal radiation therapy for treatment of primary and secondary liver cancer
Surefire infusion system safe and effective for delivery of Y90

Surefire infusion system safe and effective for delivery of Y90

Wednesday, 10 Jul 2013
Case reports published in the Journal of Cardiovascular and Interventional Radiology show that the Surefire Infusion System can safely and effectively Y90 in order to treat inoperable liver cancer. Surefire infusion system safe and effective for delivery of Y90
Sirtex to distribute Surefire Medical’s infusion system in Australia and Asia-Pacific markets

Sirtex to distribute Surefire Medical’s infusion system in Australia and Asia-Pacific markets

Wednesday, 26 Jun 2013
Sirtex Medical and US-based Surefire Medical has announced a sales and marketing partnership to distribute Surefire’s range of innovative infusion systems and specialty catheters for the interventional radiology and oncology markets. Sirtex to distribute Surefire Medical’s infusion system in Australia and Asia-Pacific markets
SARAH study enroling patients throughout France for the treatment of primary liver cancer

SARAH study enroling patients throughout France for the treatment of primary liver cancer

Tuesday, 25 Jun 2013
Launched by the Assistance Publique Hôpitaux de Paris, France, in December 2011, SARAH (Sorafenib versus radioembolization in advanced hepatocellular carcinoma), a French national collaborative randomised controlled trial of radioembolization with yttrium-90 resin microspheres vs. sorafenib in advanced hepatocellular carcinoma has announced it is seeking to enrol 400 patients. SARAH study enroling patients throughout France for the treatment of primary liver cancer
Radiosurgery treatments for lung cancer using Varian Medical Systems Technologies presented at ESTRO

Radiosurgery treatments for lung cancer using Varian Medical Systems Technologies presented at ESTRO

Tuesday, 07 May 2013
Cancer experts have reported future trends and progress in radiotherapy treatments for lung cancer using motion management and tumour-tracking technologies from Varian Medical Systems at the annual ESTRO Forum (19–23 April 2013, Geneva, Switzerland). Radiosurgery treatments for lung cancer using Varian Medical Systems Technologies presented at ESTRO
Found: 150   Displaying: 21-40
Results: 1 2 3 4 5 Next Go to:

Related Section


Clinical Trials
Interventional Oncology News
Interventional Oncology Supplement
Key Opinion Leaders discuss the role of Biocompatible's DC Bead at CIRSE and ILCA
IR Views
Literature
Oncology Useful Links

Related Feeds


Most popular


DEFINITIVE LE study results show directional atherectomy is safe and effective in claudication and critical limb ischaemia patients
Friday, 29 Aug 2014
The multicentre, 800-patient study also demonstrated that directional atherectomy was non-inferior for treating peripheral arterial disease in patients with diabetes compared with those without ... DEFINITIVE LE study results show directional atherectomy is safe and effective in claudication and critical limb ischaemia patients

First varicose vein patient treated with FDA-approved Varithena (polidocanol injectable foam) 1%
Tuesday, 12 Aug 2014
The first varicose vein patient has been treated with Varithena, the only FDA-approved foam for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities ... First varicose vein patient treated with FDA-approved Varithena (polidocanol injectable foam) 1%

Friday, 01 Aug 2014
ArtVentive has announced positive clinical results in conjunction with expanded enrolment in the ArtVentive Endoluminal Occlusion System (EOS device) OCCLUDE I post-market surveillance study. ArtVentive announces positive clinical results and expanded enrolment in OCCLUDE I post-market surveillance study

Features


The promise of chemical renal denervation
Friday, 05 Sep 2014
Tim A Fischell writes that chemical renal denervation using ethanol may have numerous advantages over energy-based “burning” technologies. The promise of chemical renal denervation

Is all heat the same and does catheter design matter?
Wednesday, 13 Aug 2014
Mark S Whiteley writes that it is essential that every doctor practising varicose vein surgery has a good understanding of the principles of endovenous thermoablation. Is all heat the same and does catheter design matter?

Profiles


Bien Soo Tan
Friday, 16 May 2014
Bien Soo Tan, senior consultant, Department of Diagnostic Radiology, Singapore General Hospital, S... Bien Soo Tan

James B Spies
Friday, 16 May 2014
The evolution of embolization over the past decade has been remarkable and it has fundamentally ... James B Spies

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions